C-Path Partners with CHDR to Expand Global Collaborations

The Critical Path Institute and the Centre for Human Drug Research (CHDR) have joined forces to expand global collaborations for both organizations.

The initiative brings together stakeholders from each side with the objective of increasing actionable solutions for drug development and public health. The partnership allows CHDR to become involved in other areas of interest within C-Path, including but not limited to, regulatory science, science education development, data sharing and data analytics and wearable technologies.

“We are excited to work with the Centre for Human Drug Research,” said C-Path President and CEO Joseph Scheeren, Pharm.D. “The collaboration aligns with our mission as an organization and will support C-Path’s continued efforts to facilitate medical innovation through sharing of data and analytics, knowledge and expertise.”

The initiative will allow CHDR to become involved in various C-Path consortia. “As a leading institute in early-stage clinical drug research, CHDR is excited to bring its data and experience to C-Path,” said CHDR CEO Koos Burggraaf, M.D., Ph.D. “We hope this partnership sparks growth and innovation for both teams as we look to the future of human drug research, including advancements in technology and clinical trial design.”

About CHDR:

Based in Leiden, the Netherlands, the Centre for Human Drug Research is an independent institute that specializes in cutting-edge, early-stage clinical drug research. Combining innovative methods and technologies, state-of-the-art facilities, and talented, motivated researchers helps CHDR maximize their clients’ success. Visit https://chdr.nl.